CHI Advisors LLC
- SEC CIK
- 0001791468
- Latest filing
- Nov 13, 2023
Holdings in Q3 2023
Holdings as of Sep 30, 2023, filed Nov 13, 2023. Long positions only; changes compare share counts with Q2 2023.
- Positions
- 26
- +1 vs. Q2 2023
- Portfolio value
- $252.1M
- −$77.3M (−23.5%) vs. Q2 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| DTILPrecision Biosciences Inc | COM | 606,629 | $207.0K | 0.1% | −996,928−62.2% | Reduced | History |
| Freeline Therapeutics Hldgs35655L206 | SPONSORED ADS | 86,654 | $372.6K | 0.1% | +64,988+300.0% | Added | – |
| LENZLENZ Therapeutics, Inc. | COM | 230,938 | $572.7K | 0.2% | 00.0% | Unchanged | History |
| IRONDisc Medicine, Inc. | COM | 25,000 | $1.17M | 0.5% | −100,139−80.0% | Reduced | History |
| RLYBRallybio Corp | COM | 390,734 | $1.32M | 0.5% | −152,040−28.0% | Reduced | History |
| BDTXBlack Diamond Therapeutics, Inc. | COM | 720,000 | $2.07M | 0.8% | −30,000−4.0% | Reduced | History |
| OMGAOmega Therapeutics, Inc. | COMMON STOCK | 1,055,882 | $2.27M | 0.9% | 00.0% | Unchanged | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 348,842 | $3.07M | 1.2% | +348,842 | New | History |
| OVIDOvid Therapeutics Inc. | COM | 864,822 | $3.32M | 1.3% | 00.0% | Unchanged | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 60,000 | $3.42M | 1.4% | +60,000 | New | History |
| TSVT2seventy bio, Inc. | COMMON STOCK | 1,002,007 | $3.93M | 1.6% | +150,000+17.6% | Added | History |
| Direxion Shs ETF Tr25460G716 | DAILY S&P BIOTEC | 225,000 | $4.63M | 1.8% | −100,000−30.8% | Reduced | – |
| BPMCBlueprint Medicines Corp | COM | 92,888 | $4.66M | 1.9% | +92,888 | New | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 1,299,359 | $5.12M | 2.0% | +531,914+69.3% | Added | History |
| INZYInozyme Pharma, Inc. | COM | 1,270,027 | $5.33M | 2.1% | +75,000+6.3% | Added | History |
| MLYSMineralys Therapeutics, Inc. | COM | 568,379 | $5.41M | 2.1% | +568,379 | New | History |
| CMPXCompass Therapeutics, Inc. | COM | 2,829,712 | $5.57M | 2.2% | 00.0% | Unchanged | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 215,000 | $7.66M | 3.0% | +130,000+152.9% | Added | History |
| IMAImageneBio, Inc. | COM | 2,180,934 | $9.44M | 3.7% | +58,894+2.8% | Added | History |
| KROSKeros Therapeutics, Inc. | COM | 407,633 | $13.0M | 5.2% | +5,515+1.4% | Added | History |
| LRMRLarimar Therapeutics, Inc. | COM | 3,414,468 | $13.5M | 5.4% | 00.0% | Unchanged | History |
| ORTXOrchard Therapeutics plc | SPON ADS NEW | 12,315,654 | $14.0M | 5.6% | +11,559,916+1,529.6% | Added | History |
| SLRNACELYRIN, Inc. | COM | 2,262,990 | $23.0M | 9.1% | −400,816−15.0% | Reduced | History |
| CGEMCullinan Therapeutics, Inc. | COM | 3,414,189 | $30.9M | 12.3% | 00.0% | Unchanged | History |
| RPTXRepare Therapeutics Inc. | COM | 2,966,674 | $35.8M | 14.2% | −32,060−1.1% | Reduced | History |
| PLRXPliant Therapeutics, Inc. | COM | 3,014,199 | $52.3M | 20.7% | −102,818−3.3% | Reduced | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q2 2023 (3)
Positions held at the end of Q2 2023 that are gone from this filing.